Claudio Gómez-Alegría

Claudio Gómez-Alegría

Auto-generated profile, based on publicly available information

Claudio Gómez-Alegría

UNIMOL Research Group, Universidad Nacional de Colombia, Bogotá, Colombia

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CEChristian Erxleben
Christian Erxleben
YLYanhong Liao
Yanhong Liao
SGSaverio Gentile
Saverio Gentile
DCDavid Chin
David Chin
CGClaudio Gomez-Alegria
Claudio Gomez-Alegria
DADavid L. Armstrong
David L. Armstrong
Calcium channels in the plasma membrane rarely remain open for much more than a millisecond at any one time, which avoids raising intracellular calcium to toxic levels. However, the dihydropyridine-sensitive calcium channels of the CaV1 family, which selectively couple electrical excitation to endocrine secretion, cardiovascular contractility, and neuronal transcription, have a unique second mode of gating, “mode 2,” that involves frequent openings of much longer duration. Here we report that two human conditions, cyclosporin neurotoxicity and Timothy syndrome, increase mode 2 gating of the recombinant rabbit CaV1.2 channel. In each case, mode 2 gating depends on a Ser residue at the cytoplasmic end of the S6 helix in domain I (Ser-439, Timothy syndrome) or domain IV (Ser-1517, cyclosporin). Both Ser reside in consensus sequences for type II calmodulin-dependent protein kinase. Pharmacologically inhibiting type II calmodulin-dependent protein kinase or mutating the Ser residues to Ala prevents the increase in mode 2 gating. We propose that aberrant phosphorylation, or “phosphorylopathy,” of the CaV1.2 channel protein contributes to the excitotoxicity associated with Timothy syndrome and with chronic cyclosporin treatment of transplant patients.

1 November 2006 in Experimental Cell Research
Verified
Journal Article
Closed access
TRTanya A. Rege
Tanya A. Rege
MPManuel Antonio Pallero
Manuel Antonio Pallero
CGClaudio Gomez
Claudio Gomez
HGHernan E. Grenett
Hernan E. Grenett
JMJoanne E. Murphy-Ullrich
Joanne E. Murphy-Ullrich
JHJames S. Hagood
James S. Hagood

1 August 1994 in FEBS Letters
Verified
Journal Article
Closed access
CTClaudio Tapia
Claudio Tapia
TFTerence Featherstone
Terence Featherstone
CGClaudio Gómez
Claudio Gómez
PTPatricia Taillon-Miller
Patricia Taillon-Miller
CACatherine C. Allende
Catherine C. Allende
JAJorge E. Allende
Jorge E. Allende

24 February 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CEChristian Erxleben
Christian Erxleben
CGClaudio Gomez-Alegria
Claudio Gomez-Alegria
TDThomas Darden
Thomas Darden
YMYasuo Mori
Yasuo Mori
LBLutz Birnbaumer
Lutz Birnbaumer
DADavid L. Armstrong
David L. Armstrong
Dihydropyridine-sensitive, voltage-activated calcium channels respond to membrane depolarization with two distinct modes of activity: short bursts of very short openings (mode 1) or repetitive openings of much longer duration (mode 2). Here we show that both the dihydropyridine, BayK8644 (BayK), and the inhibitor of Ser/Thr protein phosphatases, okadaic acid, have identical effects on the gating of the recombinant cardiac calcium channel, Ca V 1.2 (α 1 C). Each produced identical mode 2 gating in cell-attached patches, and each prevented rundown of channel activity when the membrane patch was excised into ATP-free solutions. These effects required Ser or Thr at position 1142 in the domain III pore loop between transmembrane segments S5 and S6, where dihydropyridines bind to the channel. Mutation of Ser-1142 to Ala or Cys produced channels with very low activity that could not be modulated by either BayK or okadaic acid. A molecular model of Ca V 1.2 indicates that Ser-1142 is unlikely to be phosphorylated, and thus we conclude that BayK binding stabilizes mode 2 gating allosterically by either protecting a phospho Ser/Thr on the α 1 C subunit or mimicking phosphorylation at that site.

2 October 2023 in Journal of Ultrasound
Verified
Journal Article
Open access
PDF file
CGCristian Arvey Guzmán-David
Cristian Arvey Guzmán-David
HRHéctor Andrés Ruiz-Ávila
Héctor Andrés Ruiz-Ávila
DCDiana Alexandra Camargo-Rojas
Diana Alexandra Camargo-Rojas
CGClaudio Jaime Gómez-Alegría
Claudio Jaime Gómez-Alegría
EHEDGAR HERNANDEZ
EDGAR HERNANDEZ
Purpose: Muscular atrophy implies structural and functional alterations related to muscular force production and movement. This condition has been reported to be the main reason for generalized muscle weakness; it reflects the severity of the disease and can have a profound impact on short- and long-term clinical outcomes. The purpose of this study was to determine whether muscle atrophy ultrasound parameters early predict muscle weakness, morbidity, or 28-days mortality. Methods: This was a prospective, observational single center cohort study. Ultrasound was used to determine the cross-sectional area and muscle thickness of the rectus femoris on the first and third day of ICU stay. The main outcome was the incidence of significant muscle atrophy (≥ 10%). Results: Ultrasound measurements were made in 31 patients, 58% (18/31) of which showed significant muscle atrophy. The relative loss of muscle mass per day was 1.78 at 5% per day. The presence of muscle atrophy presents increased risk for limb muscle weakness and handgrip weakness. The 28-days mortality rate was similar in both subgroups. Conclusion: The presence of muscle atrophy presents an increased clinical risk for the development of limb ICUAW and handgrip, although these observations were not statistically significant. The results could be used to plan future studies on this topic.

29 October 2018 in Metabolic Syndrome and Related Disorders
Verified
Journal Article
Open access
GMGustavo Mora-Garcia
Gustavo Mora-Garcia
DGDoris Gómez-Camargo
Doris Gómez-Camargo
ÁAÁngelo Alario
Ángelo Alario
CGClaudio Gómez-Alegría
Claudio Gómez-Alegría
Background: The caveolin 1 ( CAV1 ) gene has been associated with metabolic traits in animal models and human cohorts. Recently, a prevalent variant in CAV1 has been found to be related to metabolic syndrome in Hispanics living in North America. Since Hispanics represent an admixed population at high risk for cardiovascular diseases, in this study a Latin American population with a similar genetic background was assessed. Objective: To analyze a genetic association between CAV1 and metabolic traits in an admixed Latin American population. Methods: A cross-sectional study was carried out with adults from the Colombian Caribbean Coast, selected in urban clusters and work places through a stratified sampling to include diverse ages and socioeconomic groups. Blood pressure and waist circumference were registered. Serum concentrations of glucose, triglycerides, and high-density lipoprotein cholesterol were measured from an 8-hr fasting whole-blood sample. Two previously analyzed CAV1 single nucleotide polymorphisms were genotyped (rs926198 and rs11773845). A logistic regression model was applied to estimate the associations. An admixture adjustment was performed through a Bayesian model. Results: A total of 605 subjects were included. rs11773845 was associated with hypertriglyceridemia [odds ratio (OR) = 1.33, p = 0.001] and the metabolic syndrome (OR = 1.53, p = 0.02). When admixture adjustment was performed these genetic associations preserved their statistical significance. There were no significant associations between rs926198 and metabolic traits. Conclusions: The CAV1 variation rs11773845 was found to be consistently associated with high serum triglycerides and the metabolic syndrome. This is the first report of a relationship between CAV1 variants and serum triglycerides in Latin America.